New law­suit ac­cus­es GSK of 'de­vice hop­ping' to block gener­ic in­haler com­pe­ti­tion

De­spite in­halers be­ing on the mar­ket for decades, many pa­tients still can’t af­ford them. A new law­suit filed in Mis­souri fed­er­al court puts the blame on GSK.

Last week, plain­tiff El­liot Con­rad Dale — who’s paid for GSK’s Ven­tolin and Ar­nu­ity El­lip­ta in­halers — filed a class-ac­tion law­suit against the phar­ma gi­ant, ac­cus­ing it of schem­ing to block gener­ic ver­sions of its brand-name in­halers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER